Department of Experimental Medical Science, Lund University, Lund, Sweden.
Respir Res. 2010 May 9;11(1):54. doi: 10.1186/1465-9921-11-54.
It is widely assumed that apoptosis of eosinophils is a central component of resolution of allergic airway disease. However, this has not been demonstrated in human allergic airways in vivo. Based on animal in vivo observations we hypothesised that steroid-induced resolution of human airway eosinophilic inflammation involves inhibition of CCL5 (RANTES), a CC-chemokine regulating eosinophil and lymphocyte traffic, and elimination of eosinophils without evident occurrence of apoptotic eosinophils in the diseased tissue.
To determine mucosal eosinophilia, apoptotic eosinophils, general cell apoptosis and cell proliferation, and expression of CCL5 and CCL11 (eotaxin) in human allergic airway tissues in vivo at resolution of established symptomatic eosinophilic inflammation.
Twenty-one patients with intermittent (birch and/or grass) allergic rhinitis received daily nasal allergen challenges for two seven days' periods separated by more than two weeks washout. Five days into these "artificial pollen seasons", nasal treatment with budesonide was instituted and continued for six days in a double blinded, randomized, placebo-controlled, and crossover design. This report is a parallel group comparison of nasal biopsy histochemistry data obtained on the final day of the second treatment period.
Treatments were instituted when clinical rhinitis symptoms had been established. Compared to placebo, budesonide reduced tissue eosinophilia, and subepithelial more than epithelial eosinophilia. Steroid treatment also attenuated tissue expression of CCL5, but CCL11 was not reduced. General tissue cell apoptosis and epithelial cell proliferation were reduced by budesonide. However, apoptotic eosinophils were not detected in any biopsies, irrespective of treatment.
Inhibition of CCL5-dependent recruitment of cells to diseased airway tissue, and reduced cell proliferation, reduced general cell apoptosis, but not increased eosinophil apoptosis, are involved in early phase steroid-induced resolution of human allergic rhinitis.
人们普遍认为嗜酸性粒细胞的凋亡是过敏性气道疾病缓解的核心组成部分。然而,这在人类过敏性气道疾病中尚未得到证实。基于动物体内观察到的现象,我们假设类固醇诱导的人类气道嗜酸性粒细胞炎症的缓解涉及抑制趋化因子 CCL5(RANTES),这是一种调节嗜酸性粒细胞和淋巴细胞迁移的 CC 趋化因子,以及消除嗜酸性粒细胞,而在病变组织中没有明显发生凋亡的嗜酸性粒细胞。
确定在已建立的症状性嗜酸性粒细胞炎症缓解时,人类过敏性气道组织中粘膜嗜酸性粒细胞增多、凋亡的嗜酸性粒细胞、一般细胞凋亡和细胞增殖,以及趋化因子 CCL5 和 CCL11(嗜酸性粒细胞趋化因子)的表达。
21 例间歇性(桦树和/或草)过敏性鼻炎患者接受了为期两周以上的洗脱期后,连续两个为期七天的每日鼻过敏原挑战。在这些“人工花粉季节”的第五天,开始进行布地奈德鼻内治疗,并在双盲、随机、安慰剂对照和交叉设计中持续六天。本报告是在第二次治疗期的最后一天获得的鼻活检组织化学数据的平行组比较。
在临床鼻炎症状已经确立时开始治疗。与安慰剂相比,布地奈德减少了组织嗜酸性粒细胞增多,并且亚上皮多于上皮嗜酸性粒细胞增多。类固醇治疗也减弱了组织中 CCL5 的表达,但 CCL11 没有减少。布地奈德减少了组织中的一般细胞凋亡和上皮细胞增殖。然而,在任何活检中都没有检测到凋亡的嗜酸性粒细胞,无论治疗如何。
抑制 CCL5 依赖性细胞向病变气道组织的募集,以及减少细胞增殖、减少一般细胞凋亡,但不增加嗜酸性粒细胞凋亡,参与了早期类固醇诱导的人类过敏性鼻炎的缓解。